Dual EGFR-TGFβ Blockade Achieves 54% Response Rate in Hard-to-Treat Head and Neck Cancer
Ficerafusp alfa plus pembrolizumab shows striking results in HPV-negative head and neck cancer, a notoriously difficult-to-treat population.
Résumé
A new combination therapy pairing ficerafusp alfa — a bispecific antibody that blocks both EGFR and TGF-β — with the checkpoint inhibitor pembrolizumab showed strong early results in patients with recurrent or metastatic head and neck squamous cell carcinoma. In the 28 HPV-negative patients, who typically respond poorly to immunotherapy, the objective response rate was 54%, including 21% complete responses. Median overall survival reached 21.3 months — a meaningful improvement over historical benchmarks. Side effects were manageable, with no unexpected safety signals. These two-year results from a Phase I/Ib trial support advancing this combination into larger studies, and may represent a significant shift in how HPV-negative head and neck cancer is treated in the first-line setting.
Résumé détaillé
Head and neck squamous cell carcinoma that has recurred or spread to distant sites carries a grim prognosis, especially in patients whose tumors are not driven by HPV. In this population, high levels of EGFR and TGF-β actively suppress immune cell infiltration into tumors, blunting the effectiveness of standard immunotherapy. A novel bispecific antibody, ficerafusp alfa, was designed to simultaneously neutralize both pathways, potentially restoring immune access to the tumor microenvironment.
This expansion cohort from a Phase I/Ib trial enrolled 42 patients with PD-L1-positive recurrent or metastatic HNSCC between February 2022 and April 2023. Patients received ficerafusp alfa 1,500 mg weekly plus pembrolizumab 200 mg every three weeks as first-line therapy. After a median follow-up of 26.3 months, efficacy was assessed in 39 patients with at least one post-baseline scan.
The results in HPV-negative patients were particularly striking. Of 28 evaluable patients, 54% achieved an objective response, including 21% complete responses — a high bar in this disease. Median duration of response was 21.7 months, median progression-free survival was 9.9 months, and median overall survival reached 21.3 months. By contrast, HPV-positive patients had a lower 27% response rate, possibly reflecting a different immunological baseline. Safety was acceptable: 45% of patients experienced grade 3 treatment-related adverse events, predominantly anemia and acneiform dermatitis, with only one grade 4 event.
These findings are clinically meaningful because HPV-negative HNSCC has historically responded poorly to checkpoint inhibitor monotherapy. The dual blockade strategy appears to overcome key mechanisms of immune evasion specific to this subtype.
Caveats include the single-arm, non-randomized design and modest sample size, which limit definitive conclusions. The summary is based on abstract data only, and full trial data have not been independently reviewed here.
Principales conclusions
- 54% objective response rate in HPV-negative R/M HNSCC patients, including 21% complete responses.
- Median overall survival of 21.3 months in HPV-negative subgroup — notably high for this poor-prognosis population.
- Median duration of response reached 21.7 months, suggesting durable disease control in responders.
- Grade ≥3 adverse events in 45% of patients, mostly anemia and acneiform dermatitis — no unexpected toxicities.
- HPV-positive patients had lower 27% ORR, suggesting the dual EGFR-TGFβ blockade targets HPV-negative biology specifically.
Méthodologie
This is an expansion cohort of a first-in-human Phase I/Ib trial (NCT04429542) enrolling 42 PD-L1-positive R/M HNSCC patients treated with ficerafusp alfa plus pembrolizumab as first-line therapy. Primary endpoint was safety; secondary endpoints included ORR, PFS, DOR, and OS. Median follow-up was 26.3 months, with efficacy assessed in 39 patients with at least one post-baseline scan.
Limites de l'étude
The study is a non-randomized, single-arm expansion cohort with only 42 patients, precluding direct comparison to standard-of-care pembrolizumab monotherapy. Small subgroup sizes, particularly 11 HPV-positive patients, limit subgroup conclusions. This summary is based on the abstract only, as the full manuscript was not available for review.
Ce résumé vous a plu ?
Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.
Saisissez votre e-mail pour vous abonner :